Site-Specific Crosslinking of Antibodies
AssigneeLife Technologies Corporation
InventorsBrian Agnew, Robert Aggeler, Rolando Brawer
Life of this patent
Estimating the term…
Abstract
Methods are provided for making bispecific antibodies and antibody conjugates comprising site-specifically cross-linking two or more antibodies, antibody fragments or Fc-fusion proteins. Also provided are compositions and uses for the bispecific antibodies and antibody conjugates. The bispecific antibodies may be used to treat a disease or condition. Also provided are methods for site-specifically conjugating a liposome, an mRNA or an siRNA to an antibody, and uses of the antibody-conjugated liposome, mRNA or siRNA.
Claims32
A method of making a bispecific antibody or antibody conjugate, the method comprising:
- a) providing:
- a first antibody fragment comprising a terminal GlcNAc residue, or
- a first Fc-fusion protein comprising a terminal GlcNAc residue;
- b) contacting the first antibody fragment or first Fc-fusion protein with a modified sugar comprising a chemical handle and a galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes the attachment of the first modified sugar to the terminal GlcNAc residue of the first antibody fragment or first Fc-fusion protein thereby forming a first modified antibody fragment or a first modified Fc-fusion protein;
- c) providing a first activating molecule comprising a first crosslinking group, a first reactive group, and optionally a linker;
- d) contacting the first modified antibody fragment or first modified Fc-fusion protein with the first activating molecule, wherein the first activating molecule reacts with the first chemical handle of the first modified antibody fragment or first modified Fc fusion protein, thereby forming a first activated antibody fragment or first activated Fc-fusion protein;
- e) providing:
- a second antibody fragment comprising a terminal GlcNAc residue, or
- a second Fc-fusion protein comprising a terminal GlcNAc residue;
- f) contacting the second antibody fragment or second Fc-fusion protein with the modified sugar and the galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes attachment of the modified sugar to the terminal GlcNAc residue of the second antibody fragment or second Fc-fusion protein thereby forming a second modified antibody fragment or a second modified Fc-fusion protein;
- g) providing a second activating molecule comprising a second crosslinking group, a second reactive group and optionally a linker;
- h) contacting the second modified antibody fragment or second modified Fc-fusion protein with the second activating molecule, wherein the second activating molecule reacts with the second chemical handle of the second modified antibody fragment or second modified Fc-fusion protein, thereby forming a second activated antibody fragment or a second activated Fc-fusion protein;
- and
- i) contacting the first activated antibody fragment or first activated Fc-fusion protein with the second activated antibody fragment or second activated Fc-fusion protein, wherein the first crosslinking group of the first activated antibody fragment or first activated Fc-fusion protein reacts with the second crosslinking group of the second activated antibody fragment or second activated Fc-fusion protein, thereby forming the bispecific antibody or antibody conjugate.
(canceled)
6-10. (canceled)
(canceled)
16-18. (canceled)
22-31. (canceled)
33-42. (canceled)
44-51. (canceled)
53-57. (canceled)
59-124. (canceled)
A method of treating a disease, disorder or condition in a subject in need thereof comprising administering the bispecific antibody or antibody conjugate of claim 139.
126-130. (canceled)
A method of diagnosing a disease, disorder or condition in a subject, the method comprising:
- (a) contacting a sample obtained from a subject suspected of having the disease with the bispecific antibody or antibody conjugate of claim 139 to form a contacted sample;
- (b) incubating the contacted sample for an appropriate amount of time to form an incubated sample;
- (c) illuminating the incubated sample with an appropriate wavelength to form an illuminated sample;
- and
- (d) detecting fluorescent emissions from the illuminated sample;
- wherein the fluorescent emissions are used to diagnose or detect the disease.
132-133. (canceled)
A method for screening bispecific antibodies and antibody conjugates, the method comprising:
- a) providing:
- a first antibody comprising a terminal GlcNAc residue,
- a first antibody fragment comprising a terminal GlcNAc residue, or
- a first Fc-fusion protein comprising a terminal GlcNAc residue;
- b) contacting the first antibody, first antibody fragment or first Fc-fusion protein with a modified sugar comprising a chemical handle and a galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes attachment of the modified sugar to the terminal GlcNAc residue of the first antibody, first antibody fragment or first Fc-fusion protein thereby forming a first modified antibody, a first modified antibody fragment or a first modified Fc-fusion protein;
- c) providing a first activating molecule comprising a first crosslinking group, a first reactive group, and optionally a linker;
- d) contacting the first modified antibody, first modified antibody fragment or first modified Fc-fusion protein with the first activating molecule, wherein the first activating molecule reacts with the first chemical handle of the first modified antibody, first modified antibody fragment or first Fc-fusion protein at the first chemical handle, thereby forming a first activated antibody, first activated antibody fragment or first activated Fc-fusion protein;
- e) providing:
- a second antibody comprising a terminal GlcNAc residue,
- a second antibody fragment comprising a terminal GlcNAc residue, or
- a second Fc-fusion protein comprising a terminal GlcNAc residue;
- f) contacting the second antibody, second antibody fragment or second Fc-fusion protein with the modified sugar and the galactosyl transferase enzyme, wherein the galactosyl transferase enzyme catalyzes attachment of the modified sugar to the terminal GlcNAc residue of the second antibody thereby forming a second modified antibody, a second modified antibody fragment or a second modified Fc-fusion protein;
- g) providing a second activating molecule comprising a second crosslinking group, a second reactive group and optionally, a linker;
- h) contacting the second modified antibody, second modified antibody fragment or second modified Fc-fusion protein with the second activating molecule, wherein the second activating molecule reacts with the second chemical handle of the second modified antibody, second modified antibody fragment or second modified Fc-fusion protein at the second chemical handle, thereby forming a second activated antibody, a second activated antibody fragment or a second modified Fc-fusion protein;
- i) contacting the first activated antibody, first activated antibody fragment or first activated Fc-fusion protein with the second activated antibody, second activated antibody fragment or second activated Fc-fusion protein, wherein the first crosslinking group of the first activated antibody, first activated antibody fragment or first activated Fc-fusion protein reacts with the second crosslinking group of the second activated antibody, second activated antibody fragment or second activated Fc-fusion protein, thereby forming the bispecific antibody or antibody conjugate;
- and
- j) analyzing the bispecific antibodies or antibody conjugates for functionality.
135-138. (canceled)
A bispecific antibody or antibody conjugate comprising:
- a first activated antibody, antibody fragment or Fc-fusion protein comprising a first activating molecule;
- and
- a second activated antibody, antibody fragment or Fc-fusion protein comprising a second activating molecule;
- wherein the first activated antibody, antibody fragment or Fc-fusion protein and the second activated antibody, antibody fragment or Fc-fusion protein are crosslinked together via reaction of the first activating molecule and the second activating molecule;
- and
- wherein the first activated antibody, antibody fragment or Fc-fusion protein is crosslinked to the second antibody, antibody conjugate or Fc-fusion protein via a single crosslink.
Dependencies are inferred from the claim text.